NASHUA, N.H. and LAS VEGAS, April 26,
2017 /PRNewswire/ -- (Booth #101) -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the
Company will showcase the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at
The American Society of Breast Surgeons (ASBrS) Annual Meeting in Las Vegas, Nevada from
April 26-30, 2017. The Company will also host a series of presentations by leading clinicians at
its booth (#101) to discuss strategies and outcomes in early-stage breast cancer patient care with intraoperative radiation
therapy (IORT) using the Xoft System.
"With the growing worldwide adoption of the Xoft System, an increasing number of clinicians are recognizing that this
revolutionary technology offers a safe and effective treatment option for patients with early-stage breast cancer who meet
specific selection criteria," said Ken Ferry, CEO of iCAD. "We are pleased to highlight the unique
clinical experiences of two expert Xoft IORT breast surgeons at this year's ASBrS meeting and share in their commitment to making
innovative, clinically-proven treatment options like IORT available to their patients."
Among a range of clinical indications, the Xoft System is used to perform IORT, a procedure where breast surgeons and
radiation oncologists work together to administer one precise, concentrated dose of radiation to the tumor site at the time of
lumpectomy. Traditional breast cancer treatment involves a series of radiation treatments administered five days per week for six
to eight weeks. With traditional treatment, radiation is administered from outside the body. With IORT, radiation is delivered
from inside the tumor bed, more precisely targeting cancer cells and reducing the risk of damage to nearby healthy areas
including the heart, lungs, and ribs. A growing body of favorable clinical data supports the use of IORT in appropriate patients
with early-stage breast cancer.
Clinician experts including Craig Wengler, MD, Breast Surgeon, Martin Health System,
Stuart, FL and Janie Grumley, MD, FACS, Breast Surgeon, Virginia
Mason Hospital & Medical Center, Seattle, WA will present an overview of their recent
clinical experience treating patients with Xoft IORT in booth #101 during the meeting. The details regarding their presentations
are as follows:
Craig Wengler, MD
- Thursday, April 27, 7:30-9 pm PT
- Friday, April 28, 3:15-3:45 pm PT
Janie Grumley, MD, FACS
- Friday, April 28, 9-9:30 am PT
- Saturday, April 29, 11:45-12:30 am PT
"Our adoption of IORT with the Xoft System has allowed my practice to offer patients many unique and valuable benefits
including shorter treatment times, reduced costs, fewer side effects and added convenience compared to traditional treatment,"
said Craig Wengler, MD, Breast Surgeon, Martin Health System, Stuart,
FL. "Because the treatment is delivered in one dose, my patients are able to return to their normal daily activities
within days and better maintain their regular routine and quality of life."
In addition, researchers from Hoag Memorial Hospital Presbyterian of Newport Beach, CA will
present four-year results of their experience using the Xoft System for the treatment of early-stage breast cancer patients with
IORT in Poster #256175: Four-Year Results of a Single Site X-Ray IORT Trial for Early Breast Cancer during the Poster
Session and Reception on Saturday, April 29 from 7:30-8:30 pm PT.
The Xoft System is FDA cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere
in the body, including early-stage breast cancer, gynecological cancers and non-melanoma skin cancer.
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in a growing number of
countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological
cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise
treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding
and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to
remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple
locations and to easily store the system when not in use. The Axxent Hub is a cloud-based oncology collaboration software
solution that enables centers to monitor treatment workflow and enhance communication between clinical specialists. Xoft is a
wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and
treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer
aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers.
iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets cancer
while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the
body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive
iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer
detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks,
uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and
strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or
difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and
manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased
competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our
existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the
Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe",
"demonstrate", "intend", "expect", "would", "could", "consider", "project", "estimate", "will", "continue", "anticipate",
"likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation
to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks
faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including
the 10-K for the year ended December 31, 2016, available on the Investors section of our website at
http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
Contact:
For iCAD investor relations:
LifeSci Advisors
Bob Yedid, (646)-597-6989
Bob@lifesciadvisors.com
or
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Lynn Granito, 212-253-8881
lgranito@berrypr.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/icad-to-showcase-breakthrough-early-stage-breast-cancer-treatment-utilizing-the-xoft-system-at-american-society-of-breast-surgeons-asbrs-annual-meeting-300445950.html
SOURCE iCAD, Inc.